2016 Was a Terrible Year for Biotech but the Tweets Were on Point

2016 tweets by TheStreet's Adam Feuerstein kept us informed and entertained. From an unexpected twist on New Year's day with MannKind to J.P. Morgan's Healthcare conference to Bristol-Myers Squibb's oops!
Author:
Publish date:

2016 was a lousy year for biotech investors but TheStreet.com's Adam Feuerstein's biotech tweets were on point! It started when his beloved dog died right after New Year's Day and then MannKind (MNKD) - Get Report  went KABOOM! Another bad omen for 2016: A news-free start to the J.P. Morgan Healthcare conference, followed fast by the FDA's decision to postpone the Sarepta (SRPT) - Get Report advisory panel. The year started bad and never really stopped being bad. Let's hope 2017 is better than 2016 and the tweets keep coming @AdamFeuerstein

This article was written by a staff member of TheStreet.